TABLE 5.
Susceptibility of P. aeruginosa isolates to β-lactams alone and in combination with ciprofloxacin or tobramycin compared to susceptibility to ceftolozane-tazobactam monotherapya
| Isolate and β-lactam | % S isolates | Of BL NS isolates, % CIP S | % S to BL-CIP | Of BL NS isolates, % TOB S | % S to BL-TOB | % C-T S |
|---|---|---|---|---|---|---|
| All patient isolates | ||||||
| Cefepime | 77.0 | 39.8 | 86.2 | 78.2 | 95.0 | 96.6 |
| Ceftazidime | 77.0 | 45.7 | 87.5 | 78.9 | 95.1 | |
| Piperacillin-tazobactam | 71.8 | 49.2 | 85.7 | 80.2 | 94.4 | |
| Meropenem | 76.0 | 37.4 | 85.0 | 76.2 | 94.3 | |
| ICU patient isolates | ||||||
| Cefepime | 71.6 | 44.1 | 84.1 | 69.6 | 91.4 | 95.0 |
| Ceftazidime | 68.8 | 49.1 | 84.1 | 74.1 | 91.9 | |
| Piperacillin-tazobactam | 63.0 | 51.1 | 81.9 | 75.2 | 90.8 | |
| Meropenem | 69.9 | 38.9 | 81.6 | 69.4 | 90.8 | |
| Non-ICU patient isolates | ||||||
| Cefepime | 79.2 | 37.4 | 87.0 | 82.9 | 96.4 | 97.2 |
| Ceftazidime | 80.3 | 43.5 | 88.9 | 81.9 | 96.4 | |
| Piperacillin-tazobactam | 75.4 | 48.0 | 87.2 | 83.3 | 95.9 | |
| Meropenem | 78.4 | 36.6 | 86.3 | 79.9 | 95.7 | |
| Respiratory isolates | ||||||
| Cefepime | 69.6 | 41.6 | 82.7 | 81.2 | 94.7 | 94.7 |
| Ceftazidime | 70.0 | 45.6 | 81.6 | 81.6 | 92.4 | |
| Piperacillin-tazobactam | 63.1 | 50.3 | 81.6 | 82.9 | 93.7 | |
| Meropenem | 70.4 | 37.2 | 81.4 | 74.5 | 92.4 | |
| Nonrespiratory isolates | ||||||
| Cefepime | 81.7 | 37.9 | 88.7 | 75.0 | 95.4 | 97.8 |
| Ceftazidime | 81.5 | 45.8 | 90.0 | 76.1 | 95.6 | |
| Piperacillin-tazobactam | 77.4 | 48.0 | 88.3 | 77.5 | 94.9 | |
| Meropenem | 79.5 | 37.6 | 87.2 | 77.7 | 95.4 | |
| ICU patient respiratory isolates | ||||||
| Cefepime | 59.6 | 47.6 | 78.8 | 74.6 | 89.7 | 92.3 |
| Ceftazidime | 60.3 | 51.6 | 80.8 | 77.4 | 91.0 | |
| Piperacillin-tazobactam | 50.6 | 50.6 | 75.6 | 75.3 | 87.8 | |
| Meropenem | 59.0 | 39.1 | 75.0 | 67.2 | 86.5 | |
| ICU patient nonrespiratory isolates | ||||||
| Cefepime | 80.8 | 38.5 | 88.2 | 61.5 | 92.6 | 97.0 |
| Ceftazidime | 75.4 | 46.0 | 86.7 | 70.0 | 92.6 | |
| Piperacillin-tazobactam | 72.4 | 51.8 | 86.7 | 75.0 | 93.1 | |
| Meropenem | 78.3 | 38.6 | 86.7 | 72.7 | 94.1 | |
| Non-ICU patient respiratory isolates | ||||||
| Cefepime | 74.3 | 37.2 | 83.8 | 86.0 | 96.4 | 95.8 |
| Ceftazidime | 74.6 | 41.2 | 85.0 | 84.7 | 96.1 | |
| Piperacillin-tazobactam | 68.9 | 50.0 | 84.4 | 88.5 | 96.4 | |
| Meropenem | 75.7 | 35.8 | 84.4 | 80.2 | 95.2 | |
| Non-ICU patient nonrespiratory isolates | ||||||
| Cefepime | 82.1 | 37.6 | 88.8 | 80.2 | 96.5 | 98.0 |
| Ceftazidime | 83.7 | 45.7 | 91.1 | 79.3 | 96.6 | |
| Piperacillin-tazobactam | 79.3 | 46.2 | 88.8 | 78.6 | 95.6 | |
| Meropenem | 80.0 | 37.2 | 87.4 | 79.6 | 95.9 |
a
Definitions: BL, β-lactam; CIP, ciprofloxacin; C-T, ceftolozane-tazobactam; NS, nonsusceptible; S, susceptible; TOB, tobramycin.